Modulation of lipid metabolism for protein production

Patent metadata

Field	Value
Publication number	US-11434474-B2
Application number	US-202016818162-A
Country	US
Kind code	B2
Filing date	Mar 13, 2020
Priority date	May 3, 2016
Publication date	Sep 6, 2022
Grant date	Sep 6, 2022

Abstract

The present disclosure features methods and compositions for modulating lipid metabolism to achieve improved production and quality of recombinant products, such as next generation biologics. Modulation of lipid metabolism as described herein includes, for example, introducing a lipid metabolism modulator described herein to a cell or a cell-free system. Also encompassed by the present disclosure are engineered cells with improved production capacity and improved product quality, methods for engineering such cells, and preparations and mixtures comprising the products from such cells.

First claim

What is claimed is:

1. A eukaryotic cell comprising:
(i) a first exogenous nucleic acid encoding a first lipid metabolism modulator (LMM), wherein the first LMM comprises stearoyl CoA desaturase-1 (SCD-1), or a functional fragment or isoform thereof, the first exogenous nucleic acid being operably linked to a promoter that directs expression of the first LMM in the cell; and
(ii) a second exogenous nucleic acid encoding a recombinant therapeutic polypeptide selected from an antibody, an antibody fragment, a hormone, a blood clotting factor, a cytokine or a protein vaccine, the second exogenous nucleic acid being operably linked to a promoter that directs expression of the recombinant therapeutic polypeptide in the cell.

2. The cell of claim 1 , wherein the cell is a mammalian cell.

3. The cell of claim 2 , which is a CHO cell.

4. The cell of claim 1 , wherein the first LMM provides increased yield or rate of production of the recombinant therapeutic polypeptide as compared to a cell not having the first LMM.

5. The cell of claim 1 , wherein the first LMM provides an increased ratio of properly folded recombinant therapeutic polypeptide to misfolded or unfolded recombinant therapeutic polypeptide as compared to a cell not having the first LMM.

6. The cell of claim 1 , wherein the first exogenous nucleic acid is integrated into the chromosomal genome of the cell.

7. A method for producing a recombinant therapeutic polypeptide in a cell, the method comprising:
providing a eukaryotic cell comprising a first exogenous nucleic acid encoding a first lipid metabolism modulator (LMM) comprising stearoyl CoA desaturase-1 (SCD-1), or a functional fragment or isoform thereof; and a second exogenous nucleic acid encoding the recombinant therapeutic polypeptide, wherein the recombinant therapeutic polypeptide is selected from an antibody, an antibody fragment, a hormone, a blood clotting factor, a cytokine or a protein vaccine; and
(ii) culturing the cell under conditions where the first LMM and the recombinant therapeutic polypeptide are expressed,
thereby producing the recombinant therapeutic polypeptide.

8. The method of claim 7 , wherein the first LMM provides an increased yield or rate of production of the recombinant therapeutic polypeptide as compared to a cell not having the first LMM.

9. The method of claim 8 , wherein the yield or rate of production of the recombinant therapeutic polypeptide is increased by 100% or more, as compared to the level or quantity of polypeptide produced by a cell without the first LMM.

10. The method of claim 7 , wherein the first LMM provides an increased ratio of properly folded recombinant therapeutic polypeptide to misfolded or unfolded recombinant therapeutic polypeptide as compared to a cell not having the first LMM.

11. The method of claim 7 , wherein the first LMM comprises an amino acid sequence with at least 80% identity with the amino acid sequence of SCD-1 corresponding to SEQ ID NO: 3 or a functional fragment thereof.

12. The method of claim 11 wherein the first LMM is mouse SCD-1.

13. The method of claim 7 , wherein the cell further comprises a third exogenous nucleic acid encoding a second LMM comprising sterol regulatory element-binding transcription factor-1 (SREBF-1) or a functional fragment or isoform thereof, and in step (ii) the cell is cultured under conditions where the second LMM is expressed.

14. The method of claim 13 wherein the second LMM comprises an amino acid sequence with at least 80% identity with the amino acid sequence of SREBF1 corresponding to SEQ ID NOs: 1 or 34, or a functional fragment thereof, corresponding to SEQ ID NOs: 26, 27, or 36.

15. The method of claim 7 , wherein the nucleic acid encoding the first LMM is integrated into the chromosomal genome of the cell and the LMM is stably expressed.

16. The method of claim 7 , wherein the cell is a mammalian cell.

17. The method of claim 16 wherein the cell is a CHO cell.

18. The method of claim 7 , further comprising separating the recombinant therapeutic polypeptide from at least one cellular or medium component.

19. The method of claim 7 wherein the second exogenous nucleic acid encoding a recombinant therapeutic polypeptide has been introduced after introducing the first exogenous nucleic acid encoding the first LMM.

Assignees

• Lonza Ag

Inventors

• Budge James
• Smales Christopher Mark
• Knight Tanya Jeane
• Young Robert

Classifications

• C12P21/02 Primary

  having a known sequence of two or more amino acids, e.g. glutathione · CPC title

• C07K16/00

  Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies · CPC title

• C12N9/0071

  acting on paired donors with incorporation of molecular oxygen (1.14) · CPC title

• C12Y114/19001

  Stearoyl-CoA 9-desaturase (1.14.19.1), i.e. DELTA9-desaturase · CPC title

• C07K14/4702

  Regulators; Modulating activity · CPC title